Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for prevention of acute kidney injury risk and glycaemic management in ICU patients with type 2 diabetes
ACTRN12623000940673Phase 2Terminated
- Sponsor
- Prof Rinaldo Bellomo
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Mean daily insulin units administered while in the intensive care unit. Started Oct 2023; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12623000940673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000940673.